Arthneeti
NP

Natco Pharma Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Natco Pharma Q2 Results 2026: PAT ₹203 Cr −61%, Revenue ₹967 Cr

Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹967Cr
−29% YoY
+31.6% QoQ
Net profit
₹203Cr
−60.9% YoY
−1.9% QoQ
Margin
26.7%
−15.8 pp YoY
+1.3 pp QoQ

Based on Natco Pharma Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹809
Market cap₹15.9K Cr
P/E13.9

The short version

Total Revenue for Q2 FY27: INR 10,194 Mn, down from INR 14,630 Mn in Q2 FY26 (year-on-year decline). EBITDA for Q2 FY27: INR 3,100 Mn, down from INR 6,792 Mn in Q2 FY26 (54.4% decline).

From Natco Pharma Ltd's Q2 FY27 earnings-call transcript · updated 13 Nov 2026.

How did Natco Pharma's revenue grow in the September 2026 quarter?

  • Total Revenue for Q2 FY27: INR 10,194 Mn, down from INR 14,630 Mn in Q2 FY26 (year-on-year decline).
  • Pharmaceutical Formulations Revenue: INR 8,141 Mn in Q2 FY27 vs. INR 12,456 Mn in Q2 FY26.
  • Domestic Formulations: INR 1,457 Mn (Q2 FY27) vs. INR 1,054 Mn (Q2 FY26).
  • International Formulations: INR 6,684 Mn (Q2 FY27) vs. INR 11,402 Mn (Q2 FY26).
  • API Revenue: INR 613 Mn (Q2 FY27) vs. INR 539 Mn (Q2 FY26).

2 more points from Natco Pharma Ltd's call on revenue

Create a free account to keep reading this call

What happened to Natco Pharma's margins in Q2 FY27?

EBITDA for Q2 FY27: INR 3,100 Mn, down from INR 6,792 Mn in Q2 FY26 (54.4% decline)

Locked: what Natco Pharma Ltd said on margins

Also locked on this page: fundraising, order book

Free account, 30 seconds. No card needed.

What capex is Natco Pharma planning?

It focuses mainly on: - Investments in biotech companies like eGenesis (US$ 24.7 million total, US$ 16.7 million additional in Q2FY27). - Investments in Cellogen Therapeutics (US$ 2 million) and Stero Therapeutics (US$ 1 million).

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1Ind-Swift Laboratories
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Natco Pharma raising money or cutting debt?

See what Natco Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Natco Pharma's order book?

See what Natco Pharma Ltd said on order book & pipeline — free account, 30 seconds.

Natco Pharma Ltd — Quarterly revenue & net profit

Revenue Net profit
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27

Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the table below.

Natco Pharma Ltd Q2 FY27 results — key figures

Natco Pharma Ltd Q2 FY27 reported results vs Q2 FY26, ₹ crore
₹ CrQ2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue9671,363-29%735+31.6%
Operating profit (EBITDA)258579-55.5%187+38.3%
Operating margin26.7%42.5%-15.8 pp25.4%+1.3 pp
Profit before tax243614-60.4%186+31%
Net profit (PAT)203518-60.9%207-1.9%
EPS (₹)11.3128.94-60.9%11.53-1.9%

Source: Natco Pharma Ltd's results filing to NSE (consolidated), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹735 Cr, net profit ₹206 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

More Q2 FY27 results in Pharmaceuticals & Biotechnology

All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings

Continue your research

What Natco Pharma's management said in earlier quarters

Earlier calls (7)

Others in Pharmaceuticals & Biotechnology this season

  • Innova Captab (Q2 FY27)

    Revenue from Operations for Q2 FY27 was ₹496.3 crore, a 30.5% year-on-year (YoY) increase from ₹380.4 crore in Q2 FY26 (Page 11). Key investor presentation take

  • Viyash Scientific (Q2 FY27)

    Q2 FY27 revenue from operations: ₹9,879 million, up 16.2% YoY (Page 8) . Key investor presentation takeaways from Viyash Scientific Ltd's Q2 FY27 investor prese

  • Vineet Laborator (Q2 FY27)

    Year-on-year change: Decrease of approximately INR 323.65 lakh or about 18.58% decline . Key results statement takeaways from Vineet Laboratories Ltd's Q2 FY27

  • Balaxi Pharma (Q2 FY27)

    34.1% increase (from Rs. Key results statement takeaways from Balaxi Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Natco Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Natco Pharma Ltd Q2 FY27 results?

Total Revenue for Q2 FY27: INR 10,194 Mn, down from INR 14,630 Mn in Q2 FY26 (year-on-year decline). EBITDA for Q2 FY27: INR 3,100 Mn, down from INR 6,792 Mn in Q2 FY26 (54.4% decline).

What is Natco Pharma Ltd share price analysis?

Natco Pharma Ltd currently shows a neutral. The stock trades at a P/E of 13.9 with a market cap of ₹15,863 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Natco Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.